Melqart Asset Management’s Cytokinetics CYTK Stock Holding History

Melqart Asset Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$65.4M	Sell	767,525 -76,424	-9%	-$5.49M	6.22%	5
2026 Q1	$55.6M	Buy	843,949 +221,051	+35%	+$14M	5.48%	4
2025 Q4	$39.6M	Sell	622,898 -160,876	-21%	-$10M	3.9%	10
2025 Q3	$43.1M	Sell	783,774 -542,945	-41%	-$22.4M	5.75%	4
2025 Q2	$43.8M	Buy	1,326,719 +327,272	+33%	+$11.4M	6.26%	5
2025 Q1	$40.2M	Sell	999,447 -136,987	-12%	-$6.3M	5.24%	6
2024 Q4	$53.5M	Sell	1,136,434 -75,824	-6%	-$3.94M	6.45%	4
2024 Q3	$64M	Sell	1,212,258 -463,527	-28%	-$25.8M	5.79%	5
2024 Q2	$90.8M	Buy	1,675,785 +692,390	+70%	+$41.8M	7.51%	2
2024 Q1	$68.9M	Buy	+983,395	New	+$76.1M	4.3%	7

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Melqart Asset Management's CYTK Position: Q2 2026 in Review

Melqart Asset Management reduced its Cytokinetics (CYTK) stake by 9.1% in Q2 2026, selling an estimated $5.49M and leaving 767,525 shares worth $65.4M. The position accounts for 6.22% of the portfolio, ranked #5.

Melqart Asset Management first reported a position in CYTK in Q1 2024 and has held it in 10 quarters since. The position peaked at $90.8M in Q2 2024. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Melqart Asset Management held 767,525 shares of Cytokinetics worth $65.4M as of Q2 2026.
Melqart Asset Management sold 76,424 Cytokinetics shares in Q2 2026, an estimated $5.49M.
Cytokinetics made up 6.22% of Melqart Asset Management's portfolio in Q2 2026, its #5 holding.
Melqart Asset Management first reported a position in Cytokinetics in Q1 2024 and has held it in 10 quarters since.
Melqart Asset Management's Cytokinetics position peaked at $90.8M in Q2 2024.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Melqart Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.